We are live on ! Find out more
APM

Avidity Partners Management Portfolio holdings

AUM $936M
1-Year Est. Return 195%
This Fund
S&P 500
This Quarter Est. Return
+13.95%
1 Year Est. Return
+195%
3 Year Est. Return
+460.87%
5 Year Est. Return
+815.5%
10 Year Est. Return
–
AUM
$1.96B
AUM Growth
-$393M
Cap. Flow
-$554M
Cap. Flow %
-28.28%
Top 10 Hldgs %
32.05%
Holding
103
New
18
Increased
14
Reduced
37
Closed
22

Top Buys

Rank Stock Value
1
UNH icon
UnitedHealth
UNH
+$49.4M
2
HUM icon
Humana
HUM
+$46.2M
3
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$26.7M
4
CNTA
Centessa Pharmaceuticals
CNTA
+$26.1M
5
ORKA
Oruka Therapeutics
ORKA
+$24.6M

Top Sells

Rank Stock Value
1
CI icon
Cigna
CI
+$61M
2
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$53.9M
3
REGN icon
Regeneron Pharmaceuticals
REGN
+$50.4M
4
AVTR icon
Avantor
AVTR
+$45.4M
5
ISRG icon
Intuitive Surgical
ISRG
+$45.1M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
2 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AVTR icon
26
Avantor
AVTR
$8.03B
$31.9M 1.63%
1,235,000
-1,851,000
-60% -$45.4M
BPMC
27
DELISTED
Blueprint Medicines
BPMC
$29.1M 1.49%
315,000
-68,000
-18% -$6.75M
MIRM icon
28
Mirum Pharmaceuticals
MIRM
$6.96B
$28.5M 1.45%
731,104
– –
SGRY icon
29
Surgery Partners
SGRY
$1.98B
$26.7M 1.36%
827,000
-479,477
-37% -$14.2M
AXSM icon
30
Axsome Therapeutics
AXSM
$12.3B
$26.6M 1.36%
296,100
-79,900
-21% -$6.97M
DHR icon
31
Danaher
DHR
$138B
$26.4M 1.35%
95,000
-55,000
-37% -$14.6M
JANX icon
32
Janux Therapeutics
JANX
$950M
$25.5M 1.3%
562,000
-278,219
-33% -$12.1M
NMRA icon
33
Neumora Therapeutics
NMRA
$308M
$23.8M 1.21%
1,800,000
– –
KYMR icon
34
Kymera Therapeutics
KYMR
$9.05B
$23.7M 1.21%
+500,000
New +$22.1M
BHVN icon
35
Biohaven
BHVN
$2.18B
$23.2M 1.19%
465,000
+15,000
+3% +$584K
BMRN icon
36
BioMarin Pharmaceuticals
BMRN
$11.6B
$22.5M 1.15%
+320,000
New +$26.7M
ARGX icon
37
argenx
ARGX
$55.6B
$20.7M 1.06%
38,200
-22,300
-37% -$11.3M
INCY icon
38
Incyte
INCY
$23.7B
$20.4M 1.04%
308,110
-220,890
-42% -$14.1M
ABBV icon
39
AbbVie
ABBV
$454B
$19.7M 1.01%
100,000
-177,800
-64% -$33.2M
ORKA
40
Oruka Therapeutics
ORKA
$5.44B
$19.4M 0.99%
790,926
+707,593
+849% +$24.6M
GPCR icon
41
Structure Therapeutics
GPCR
$3.46B
$18.9M 0.96%
430,900
-644,100
-60% -$24.9M
NGNE icon
42
Neurogene
NGNE
$691M
$17.8M 0.91%
425,041
-302,496
-42% -$11.7M
TERN
43
DELISTED
Terns Pharmaceuticals
TERN
$17.8M 0.91%
+2,133,872
New +$17.6M
ASND icon
44
Ascendis Pharma A/S
ASND
$16.6B
$17.8M 0.91%
+119,000
New +$16.1M
BNTX icon
45
BioNTech
BNTX
$23B
$17.2M 0.88%
+145,000
New +$13.3M
ITCI
46
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$17M 0.87%
233,000
-167,000
-42% -$12.6M
KROS icon
47
Keros Therapeutics
KROS
$202M
$17M 0.87%
293,200
-50,000
-15% -$2.47M
DXCM icon
48
DexCom
DXCM
$28.3B
$16.1M 0.82%
240,000
-19,000
-7% -$1.56M
ORIC icon
49
Oric Pharmaceuticals
ORIC
$1.24B
$14.8M 0.76%
+1,447,119
New +$14.3M
NAMS icon
50
NewAmsterdam Pharma
NAMS
$3.53B
$14.8M 0.75%
889,700
+330,400
+59% +$5.72M
1
2
3 4 5

Similar funds

NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
PWAM
Private Wealth Asset Management Cedar Rapids, Iowa $935M AUM 17.66% 1-Year Est. Return
LJAC
L.J. Altfest & Co New York $935M AUM 27.19% 1-Year Est. Return
NI
NetEase Inc Hangzhou, China $934M AUM 11.31% 1-Year Est. Return
MCM
Massar Capital Management Stamford, Connecticut $934M AUM 14.18% 1-Year Est. Return
TS
Tamar Securities Woodland Hills, California $934M AUM 26.74% 1-Year Est. Return
TW
TritonPoint Wealth Chevy Chase, Maryland $934M AUM 23.95% 1-Year Est. Return
PGA
Portland Global Advisors Portland, Maine $938M AUM 13.22% 1-Year Est. Return

Avidity Partners Management's Q3 2024 Portfolio in Review

As of Q3 2024, Avidity Partners Management held 103 positions worth $1.96B, down 17% from $2.35B the previous quarter. Its ten largest holdings account for 32% of the portfolio.

Avidity Partners Management withdrew a net $554M in Q3 2024, closing 22 positions and reducing 37 holdings. Its most notable exit was Cigna, an estimated $61M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Technology.

Against the trend, Avidity Partners Management opened a new position in UnitedHealth worth $51.1M.

  • Avidity Partners Management's largest Q3 2024 buy was UnitedHealth: 87,400 shares worth $51.1M.
  • Avidity Partners Management added most to Oruka Therapeutics in Q3 2024, an estimated $24.6M increase.
  • Avidity Partners Management's biggest Q3 2024 reduction was Avantor, cutting an estimated $45.4M.
  • Avidity Partners Management fully exited Cigna in Q3 2024, selling an estimated $61M.
  • Avidity Partners Management's ten largest holdings make up 32% of its $1.96B portfolio in Q3 2024.
  • Avidity Partners Management opened 18 new positions and closed 22 in Q3 2024.
  • Avidity Partners Management's portfolio value fell 17% quarter-over-quarter to $1.96B.

Based on Avidity Partners Management's 13F filing for Q3 2024, filed 14 Nov 2024.